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Background: Obstructive sleep apnea (OSA) in the general community is associated with 
obesity, smoking, alcohol, and sedative medication use and contributes to depressed 
mood, daytime sedation, and sudden cardiovascular deaths. Poor cardiovascular health, 
impaired social functioning, and negative and cognitive symptoms are also among the 
common clinical features of psychotic disorders. People with psychosis have higher 
rates of sleep disturbance; however, OSA has not been extensively investigated in this 
population.
aims: This study aimed to determine the prevalence of OSA and general sleep disruption 
symptoms in a representative Australian sample of people with psychosis. We investi-
gated the prevalence of potential risk factors for OSA, including obesity, psychotropic 
medications, and substance abuse in this population. Finally, we evaluated associations 
between symptoms of OSA, symptoms of general sleep disruption, and various clinical 
features in people with psychosis.
Methods: Participants took part in the Second National Australian Survey of Psychosis, 
a population-based survey of Australians with a psychotic disorder aged 18–64 years. 
Symptoms associated with OSA (snoring and breathing pauses during sleep) in the past 
year were assessed using questions from the University of Maryland Medical Centre 
Questionnaire and symptoms associated with general sleep disruption in the past week 
using the Assessment of Quality of Life Questionnaire. Data collected included psychi-
atric diagnosis and symptoms, education, employment, medications, smoking status, 
physical activity, drug and alcohol use, and cognitive function. Physical health measures 
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inTrODUcTiOn
Obstructive sleep apnea (OSA) affects 2–4% of the general adult 
population (1). OSA is characterized by repeated pharyngeal 
obstructions during sleep, resulting in airflow cessation (apnea) 
or reduction (hypopnea), frequent disruption of sleep, and 
hypoxic episodes. While obesity is the most significant risk 
factor, other risk factors, including smoking and use of sedative 
medications, have been found to play a significant role in OSA 
(2–4). OSA is associated with poor cardiometabolic outcome (5), 
increased risk of depression and anxiety, and impaired neuro-
cognitive function (6).
People living with psychosis experience poor physical 
health and shortened life expectancy, with high prevalence of 
cardiometabolic risk factors, including obesity, hypertension, 
and diabetes (7, 8); impaired social and occupational function 
(9–11); and cognitive impairment (11, 12). Although OSA and 
psychotic disorders have many risk factors and poor clinical 
outcomes in common, few studies have focused on OSA in 
people with psychosis (13, 14). Several small studies have found 
a high prevalence of OSA in people with schizophrenia (15–18). 
High rates of obesity and smoking and frequent use of sedative 
medications observed in people with psychotic illnesses may con-
tribute to the development of OSA. Alternatively, the pathological 
sequelae of OSA, including repeated episodes of hypoxia, sleep 
fragmentation, and oxidative stress, may precipitate or perpetu-
ate psychopathological symptoms, metabolic disturbance, and 
impairment of neurocognitive and social functions in people 
with psychotic illness.
aims
Our primary aim was to examine the prevalence of OSA symp-
toms in a large representative sample of people with psychosis. 
Secondary aims included exploring the associations between 
OSA symptoms and variety of clinical outcomes, including 
physical health, risk factors for cardiovascular diseases, quality 
of life, social functioning, cognitive functioning, vocational 
engagement, and psychiatric symptoms. Finally, we examined 
the association between OSA symptoms in this population and 
known risk factors for OSA (e.g., obesity, alcohol and tobacco 
consumption, and sedative medication).
Our hypothesis was that clinical symptoms of OSA would be 
highly prevalent in people with psychosis and that clinical symp-
toms of OSA would correlate with increased cardiometabolic 
risk, poor cognitive and social functioning, and poor quality of 
life. Clinical symptoms of OSA would be associated with obesity, 
substance abuse, and the use of antipsychotic medications in a 
representative sample of people with psychotic disorders.
MaTerials anD MeThODs
sample
The 2010 Survey of High Impact Psychosis (SHIP) was the 
second Australian National survey of psychotic disorders. The 
survey catchment covered a population of 1.5 million people aged 
18–64 years, approximately 10% of the Australian population in 
this age group. A two-phase design was used. In Phase 1, screening 
for psychosis took place in public mental health services and in 
non-governmental organizations supporting people with a men-
tal illness. In Phase 2, people who screened positive for psychosis 
in Phase 1 were randomly selected and stratified by age group 
(18–34  years and 35–64  years) for interview and assessment. 
This process identified 7955 people who were screened positive 
for psychosis and eligible for interview. Potential participants 
were randomly selected and approached for participation in the 
study; 1825 participants who screened positive for psychosis were 
included and interviewed in Phase 2 of the study. The study was 
approved by the human research ethics committees at each of the 
seven study sites, and all participants provided written- informed 
consent. Full details of the survey methodology are described 
elsewhere (10, 12).
Demographics and social Participation
Gender, age, marital status, formal study educational level, and 
current employment were recorded. Item to assess the partici-
pant’s involvement in meaningful activity was extracted from the 
main interview schedule to assess: 0 = employed in any job in last 
12 months; 1 = home duties/caring for own children; 2 = caring 
included body mass index, waist circumference, blood pressure, fasting blood glucose, 
and lipids.
results: Snoring was reported by 41.9%; 7% stating they frequently stopped breathing 
(pauses) during sleep. Univariate logistic regressions show OSA symptoms (pauses and 
snoring) were associated with older age, female gender, lower levels of social participation 
or employment, cardiovascular risk factors, sedentary lifestyle, and poorer quality of life, while 
symptoms of general sleep disruption were more likely in people with depressive symptoms.
conclusion: Australians with psychosis have high levels of sleep disturbance, including 
OSA. OSA symptoms were associated with cardiovascular disease risk factors, reduced 
social participation and employment, and poorer quality of life. Whether correction of OSA 
can improve these factors in people with psychosis remains to be determined.
Keywords: risk factors, obstructive sleep apnea, psychosis, social functioning, physical health
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for relatives; 3 = retired; 4 = volunteer/unpaid work; 5 = student; 
and 6 =  no formal activity. Participants were divided into two 
groups: no formal activity and others. Diagnostic assessment 
was based on a semi-structured clinical research interview, the 
Diagnostic Interview for Psychosis (DIP) (19). Diagnoses were 
made according to the ICD-10 classification system (20).
sleep apnea risk assessment
Questions assessing sleep apnea were taken from the University of 
Maryland Medical Centre Questionnaire for Sleep Apnea. These 
were self-rated assessments of the frequency and severity of snor-
ing and pauses in breathing during sleep (a more severe symptom 
of OSA) over the previous 12 months. To assess the severity of the 
snoring, the following question was asked: “In the last 12 months, 
how frequently do you experience or have you been told about 
snoring loud enough to disturb the sleep of others?” [0 = never; 
1 = rarely (less than once a week); 2 = occasionally (1–3 times a 
week); 3 = frequently (>3 times a week)]. To assess the severity of 
pauses, the following question was asked: “In the last 12 months, 
how often have you been told that you have “pauses” in breathing 
or stop breathing during sleep?” [0 = never; 1 = rarely (less than 
once a week); 2 = occasionally (1–3 times a week); 3 = frequently 
(>3 times a week)].
The assessment of the severity of disrupted sleep in the past 
week was made using Question 13 from the Assessment of Quality 
of Life (AQoL) Questionnaire-4D (21). The severity of disrupted 
sleep was rated as 1 = “I am able to sleep without difficulty most 
of the time”; 2 = “My sleep is interrupted some of the time, but I 
am usually able to go back to sleep without difficulty”; 3 = “My 
sleep is interrupted most nights, but I am usually able to go back 
to sleep without difficulty”; 4 = “I sleep in short bursts only. I 
am awake most of the night.” Dichotomous categories for sleep 
measurement were created as follows: snoring (yes = reported 
snoring, no  =  no snoring); pauses (yes  =  reported pauses, 
no =  no pauses); disrupted sleep (yes =  at least some of the 
time, no = rarely).
Physical activities and Physical health
Physical activity in the past 7  days was assessed using the 
International Physical Activity Questionnaire (IPAQ) short 
form (22). Electronic scales measuring up to 200 kg were used 
to assess weight (kilograms); height (metres) was taken against 
a measure on a wall. Body Mass Index (BMI) was calculated 
as weight/height2. Participants were categorized according to 
WHO criteria (23) as underweight (BMI < 18.5), normal (BMI 
18.5–24.99), overweight (BMI 25–29.99) or obese (BMI ≥ 30). 
Participants’ absolute 5-year cardiovascular disease risk was 
determined by Framingham risk equation (24). Participants’ 
history of diagnosed cardiovascular disease was ascertained 
by asking participants if they had ever been told by a doctor 
that they had any of the following: heart attack, angina, stroke/
transient ischemic attack (TIA), or other heart disease, e.g., 
arrhythmias. They were asked to bring all medications to the 
interview, and those relevant to cardiometabolic conditions were 
identified. Details of all medication used in the 4 weeks prior to 
interview was recorded; this was based on self-report or review 
of medication charts (25).
Participants were also asked to provide a fasting blood sample 
for analysis of high density lipoprotein cholesterol, triglyceride, 
and plasma glucose levels. Metabolic syndrome was defined using 
the harmonized criteria developed by the International Diabetes 
Federation Task Force on Epidemiology and Prevention and 
related expert organizations (26). These criteria for metabolic 
syndrome require three of the following five risk factors to make 
the diagnosis: abdominal obesity (at-risk waist circumference 
≥94 cm for men and ≥80 cm for women); at-risk diastolic and/
or systolic blood pressure (systolic blood pressure ≥130 mmHg 
and/or a diastolic pressure ≥85 mmHg); at-risk levels of fasting 
blood glucose (≥5.6  mmol/L), triglycerides (≥1.7  mmol/L), or 
HDL-C (<1.0 mmol/L for men and <1.3 mmol/L for women). 
Abdominal obesity was defined as a waist circumference ≥94 cm 
for men and ≥80 cm for women. Hypertension was diagnosed if 
the person had a systolic blood pressure ≥130 mmHg and/or a 
diastolic pressure ≥85 mmHg. The thresholds for blood glucose, 
triglycerides, and lipids were: glucose ≥5.6 mmol/L; triglycerides 
≥1.7  mmol/; HDL-C <1.0  mmol/L for men and <1.3  mmol/L 
for women. People receiving medications for hypertension, 
hyperlipidemia, or hyperglycemia were considered to meet the 
relevant criterion.
The IPAQ short form (22) was used to assess the amount of 
time participants spent in both vigorous and moderate exercise, 
and the amount of time they spent sitting on a typical weekday, 
during the last 7 days. The total time spent in various activities 
over the previous 7 days was classified according to Australian 
Bureau of Statistics criteria as applied in the National Survey of 
Mental Health and Wellbeing (27) into four levels of activity: very 
low, low, moderate, and high.
Psychotropic Medications
Information about antipsychotics, mood stabilizers, antidepres-
sants, and other sedative medications taken in the 4 weeks prior to 
the interview was collected. Outpatients were asked to bring their 
medications to the interview, and for inpatients, the drug charts 
were reviewed. Antipsychotic medications were sub-classified as 
typical antipsychotics and atypical antipsychotics.
substance Use
Respondents were asked how often they had used alcohol, can-
nabis, amphetamines, and other drugs in the previous year, and 
were classified as: 1 = not used; 2 = monthly or less than monthly; 
3 = weekly/daily (19). Alcohol dependence and risk categories 
were measured using the Alcohol Use Disorders Identification 
Test (AUDIT) (28). Lifetime diagnoses of alcohol, cannabis, and 
other substance abuse/dependence were assessed using the DIP 
(19). Caffeine consumption was quantified based on amount per 
day on average in the previous 4 weeks.
Diagnosis, Psychopathology, and 
cognitive Function assessment
Diagnostic assessment was based on a semi-structured clinical 
research interview, the DIP (19). Diagnoses were made according 
to the ICD-10 classification system (20). Psychiatric symptoms 
were systematically interrogated using the DIP. Symptoms of 
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hallucinations, delusions, or subjective thought disorder in the 
past 1 month and symptoms of anxiety, including worry, panic, 
anxiety, and obsession over the past 12 months were recorded. 
A brief cognitive assessment tool was employed. This comprised 
the: (i) National Adult Reading Test (NART) Revised (29) and (ii) 
Digit-Symbol Coding Test (DSCT) from the RBANS battery (30). 
Participants’ subjective experience of forgetfulness over the past 
12 months prior to the interview was assessed and the results were 
classified as: 1 = able to remember most things; 2 = somewhat 
forgetful; 3 = very forgetful.
Quality of life assessment
The quality of life in the past week was assessed using The AQoL-4D 
12-item instrument (21). The AQoL-4D independently models 
all the sub-dimensions of health (independent living, social rela-
tionships, physical senses, psychological well-being, and illness) 
and combines sub-models to obtain a multi-attribute utility score. 
Scores from the first four dimensions form the multi-attribute 
utility score. Algorithms for AQoL scoring were obtained from 
http://www.aqol.com.au/index.php/scoring-algorithms?id=82. 
Where negatively skewed (AQoL utility scores), data were trans-
formed using the appropriate log transformations.
statistical analyses
Descriptive statistics were reported as means and SDs. 
Dichotomous categories were created: age (18–34 vs. 35–64); 
obesity – BMI ≥ 30 (no vs. yes); absolute 5-year cardiovascular 
disease risk by Framingham risk equation (low vs. high = medium 
risk or high risk); any formal activity, including paid or unpaid 
work, or study (no vs. yes); subjective memory forgetfulness 
(no = able to remember most things vs. yes = somewhat forgetful 
or very forgetful); Fagerstrom nicotine dependence categories 
(low = low or very low vs. high = moderate, high, or very high); 
AUDIT risk (low vs. high = hazardous, harmful, or dependent). 
Univariate logistic regression was performed to explore associa-
tions between and among potential risk factors (independent 
variables) and the dependent variables (sleep apnea – snore, 
sleep apnea – pause, and disrupted sleep). Independent samples 
t-test was used to compare the mean scores for the AQoL. A 
binary logistic regression analysis was conducted to explore 
potential predictors of OSA symptoms. Variables were divided 
into four categories (cardiovascular risks; physical activity; 
social function; and substance abuse) and were entered into the 
model to estimate multivariate associations, with and without 
adjusting for age, gender, and BMI. Variables were included 
in the regression analyses, if they demonstrated significant 
association with OSA symptoms in the univariate analyses. 
All statistical analyses were performed with SPSS 22.0. The α 
value taken to indicate statistical significance was adjusted using 
Bonferroni correction for multiple comparisons of variables of 
the same category.
resUlTs
sociodemographic Data
The study sample comprised 1825 participants. Their mean age 
was 38.4 ± 11.2 years, and 59.6% were male. Most participants 
were single (61.2%); only 17% were married or in de facto 
relationships. More than half (53.2%) of the participants were 
not currently engaged in any meaningful activity such as paid 
or unpaid employment, volunteer job, career, home duty, or 
study. Most did not engage with any vigorous or moderate 
physical activity (76.9 and 69.2%, respectively); around half 
(48.5%) had engaged in any form of physical activity for less 
than 2 h per week. Nearly all participants (96.7%) had very low 
to low levels of exercise, according to ABS classification (31). 
The majority of participants were overweight, with 46.4% being 
obese (BMI ≥ 30), and the mean BMI was in the obese range 
(30.5 ± 7.5 SD) (Table 1).
Prevalence of symptoms of sleep 
Disturbance
Nearly half of participants reported snoring during sleep 
(41.9%), while 17.4% reported that they stopped breathing 
during sleep and 7% reported frequent ( >3 times per week) 
episodes of stopping breathing during sleep. Over half of 
participants reported disrupted sleep at least some of the night 
(Table  2).
The association between symptoms of 
sleep Disturbance and sociodemographic 
characters
Women reported snoring more frequently than men (p < 0.001). 
Individuals aged 35–64  years had significantly higher odds of 
snoring (p <  0.001), pauses (stopped breathing during sleep) 
(p < 0.05), and disrupted sleep (p < 0.05), compared with those 
aged 18–34 years. People reporting pauses in breathing during 
sleep were less likely to have any formal work or study activity 
(p < 0.05), be in paid employment in the previous year (p < 0.01), 
or be in paid employment in the previous week (p <  0.001) 
(Table 3).
associations between cardiovascular 
risks and symptoms of sleep Disturbance
People who reported snoring or pause had 1.5–3 times odds 
than those who did not to meet at-risk criteria for most key 
cardiometabolic risk factors, including elevated plasma 
triglycerides and fasting glucose, low HDL cholesterol, and 
hypertension. Participants reported snoring had odds ratio 
(OR) of 1.84 [confidence interval (CI) 1.46, 2.32], while those 
reported pause had OR of 2.26 (CI 1.66, 3.08) to meet criteria 
for metabolic syndrome and they had a higher 5-year risk of 
cardiovascular disease [snore OR 1.56 (CI 1.23, 1.98); pause 
OD 1.65 (CI 1.23, 2.22), respectively]. Snorers were more likely 
to have reported a history of cardiovascular disease, including 
angina, heart attack, other heart disease, e.g., arrhythmias, 
hypertension, and stoke/TIA [OR 2.03 (CI 1.64, 2.52)], as did 
those who reported pauses in breathing during sleep [OR 2.19 
(CI 1.69, 2.84)]. Participants with disrupted sleep were more 
likely to meet the at-risk criteria for triglyceride levels, but not 
for other cardiovascular risk factors. Those with disrupted sleep 
were more likely to have a history of cardiovascular disease [OR 
1.47 (CI 1.19, 1.82)] (Table 4).
TaBle 2 | sleep data of the study population (present state).
N %
sleep apnea snoring
Never 1018 58.1
Rarely 185 10.6
Occasionally 213 12.2
Frequently 337 19.2
sleep apnea (pause)
Never 1418 82.6
Rarely 100 5.8
Occasionally 78 4.5
Frequently 121 7.0
Disrupted sleep
Rarely 837 46.3
Some of the night 415 23.0
Most of the night 318 17.6
Short bursts sleep 236 13.1
TaBle 1 | social demographics.
N % Mean ± sD
gender
Men 1039 59.3
Women 714 40.7
age 38.4 ± 11.2
18–34 773 42.4
35–64 1052 57.6
Marital status
Single, never married 1117 61.2
Married/de facto 312 17.0
Separated 376 20.6
Widowed 20 1.1
education level
Complete year 9 410 22.5
Complete year 10 535 29.3
Complete year 11 283 15.5
Complete year 12 574 31.5
Physical activity
Vigorous (none) 1448 79.6
Moderate (none) 1255 69.2
Walking (≤2 h/week) 942 52.3
Total activity (≤2 h/week) 881 48.5
Sitting (h/week) 45.7 ± 23.2
level of exercise (aBs classification)
Very low 611 33.6
Low 1148 63.1
Moderate 54 3
High 6 0.3
Meaningful activity (paid or unpaid 
work or study)
Yes 854 46.8
No 971 53.2
Difficulty reading, writing, or both
Yes 335 18.4
No 1490 81.6
BMi – criteria from World health 
Organization
30.5 ± 7.5
Underweight 26 1.5
Normal 409 23.1
Overweight 516 29.1
Obese 823 46.4
any history of cardiovascular 
disease (including hypertension 
and stroke)
505 28.5
Diagnosis
Schizophrenia 857 47.0
Schizoaffective disorder 293 16.1
Bipolar disorder with psychotic features 319 17.5
Depression with psychosis 81 4.4
Delusional disorder 92 5.0
Major depression without psychosis 158 8.7
Screen positive but did not meet full 
criteria for ICD-10 psychosis
25 1.4
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associations between level of 
Physical activities, Quality of life, 
Psychopathology, and symptoms 
of sleep Disturbance
Participants with pauses in breathing during sleep, but not 
snoring or interrupted, had higher odds of not to engage in any 
vigorous activity [OR 1.6 (CI 1.14, 2.26)] or total physical activity 
[OR 1.53 (CI 1.09, 2.16)]. Participants reporting pauses in breath-
ing during sleep had lower scores on measures of total quality of 
life (p < 0.001), independent living (p < 0.05), and psychological 
wellbeing (p < 0.001) when compared with those without pauses 
(Table 5).
Participants with disrupted sleep but not snoring or 
pauses in breathing during sleep had higher odds of experienc-
ing hallucinations, delusions or subjective thought disorder 
(p < 0.001), depressive symptoms (p < 0.001), and manic symp-
toms (p <  0.001) in the past month. Anxiety symptoms were 
more likely to occur in those whose sleep was characterized by 
snoring (p < 0.01), pauses (p < 0.001), and disruption (p < 0.001) 
(Table 6).
associations between Psychotropic 
Medications and symptoms of sleep 
Disturbance
Participants taking atypical antipsychotic medications (includ-
ing clozapine) had lower odds of reporting disrupted sleep than 
those not taking atypical antipsychotics (p < 0.001, respectively). 
Atypical antipsychotics were not associated with snoring or 
pauses in breathing during sleep. Mood stabilizers were associ-
ated with increased odds of snoring (p < 0.001) and pauses in 
breathing during sleep (p < 0.05), but there was no association 
with disrupted sleep. Taking an antidepressant was associated 
with an increased likelihood of snoring (p < 0.001) and a reduced 
likelihood of disrupted sleep (p < 0.001), but had no significant 
association with pauses in breathing during sleep (Table 7).
associations between substance Use and 
symptoms of sleep Disturbance
People who were at risk of hazardous/harmful/dependent 
drinking or who were current smokers were more likely to have 
pauses in breathing during sleep and disrupted sleep, while those 
who used cannabis or tranquilizers monthly or more frequently 
were more likely to have disrupted sleep. Monthly or more 
frequent amphetamine use was associated with lower incidence 
of pauses. Caffeine intake of <200 mg/day was associated with a 
TaBle 3 | Univariate associations between participant characteristics and symptoms of sleep disturbance.
snore Pause Disruptive sleep
N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci)
gender
Men 399 38.4 13*** 1.43 (1.18, 1.73) 117 17.4 0.01 1.01 (0.78, 1.30) 557 51.8 3.6 1.20 (0.99, 1.45)
Women 336 47.1 122 17.5 412 56.4
age
18–34 259 34.1 33.5*** 1.77 (1.46, 2.16) 110 14.9 5.8* 1.37 (1.06, 1.77) 390 50.7 4.7* 1.23 (1.02, 1.48)
35–64 476 47.9 189 19.3 579 55.8
lives alone
Yes 208 39.4 2.3 0.85 (0.69, 1.05) 82 15.9 1.2 0.86 (0.65, 1.13) 314 56 1.5 1.13 (0.93, 1.39)
No 514 43.3 210 18.1 637 52.8
Formal activity (paid or 
unpaid work, or study)
Yes 345 41.5 0.14 0.97 (0.8, 1.17) 122 15 6.5* 0.72 (0.56, 0.93) 450 52.9 0.39 0.94 (0.78, 1.15)
No 390 42.3 177 19.6 519 54.3
Paid employment –  
past year
Yes 232 39.9 1.4 0.88 (0.72, 108) 75 13.2 10.7** 0.62 (0.47, 0.83) 308 51.9 1.2 0.9 (0.74, 1.09)
No 503 42.9 224 19.5 661 54.5
Paid employment –  
past week
Yes 156 40.9 0.2 0.95 (0.75, 1.2) 43 11.4 12.1*** 0.55 (0.39, 0.77) 194 49.6 3.3 0.81 (0.65, 1.12)
No 579 42.2 256 19.1 775 54.8
OR, odds ratio; CI, confidence interval.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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lower incidence of snoring and pauses in breathing during sleep 
(Table 8).
Multiple logistic regression Models 
adjusting for Multiple confounders
After adjusting for gender, age, and BMI in multiple logistic 
regression models, the odds of pauses in breathing during sleep 
in participants with a positive history of cardiovascular disease 
remained 1.96 times (95% CI, 1.19, 3.48) higher than those with-
out the history of cardiovascular disease. Participants who were 
at high risk of hazardous/harmful/dependent drinking had odds 
ratio of snoring 1.59 times (CI 1.07, 2.38) and pause in breathing 
during sleep 1.882 times (CI 1.15, 3.09) in low risk participants 
(Table 9).
DiscUssiOn
In this representative sample of people with psychotic illness, 
symptoms of OSA were highly prevalent, with rates of pauses in 
breathing during sleep and snoring 17.4 and 41.9%, respectively. 
However, these results are likely to be underestimates given that 
83% of patients were neither married or in a de facto relation-
ship and, thus, likely had no regular bed partner to notice these 
symptoms during sleep. Our results confirm and add precision 
to findings from previous studies with small samples of selected 
patients with schizophrenia (15–18). Further, the prevalence of 
OSA in our study sample was much higher than the prevalence 
of OSA in general population, which is estimated to be 3–5% 
(1, 32–36).
Our study has demonstrated that symptoms of OSA (snoring 
and pauses in breathing during sleep) were associated with higher 
likelihood of meeting at-risk criteria for key cardiometabolic risk 
factors. Symptoms of OSA were associated with a higher rate of 
a reported history of cardiovascular diseases. The association 
between pause in breathing during sleep and reported history 
of cardiovascular disease remained significant after adjusting for 
BMI, age, and gender. Previous studies in the general population 
have found that OSA is a significant independent risk factor for 
CVD-related mortality and a composite endpoint of all-cause 
mortality and incident stroke (37). Additionally, obesity, male 
gender, older age, and increased neck circumference are the most 
significant risk factors for OSA. Thus, it is likely that OSA and 
obesity may impact on each other to set up a vicious cycle, thereby 
creating severe cardiometabolic disease.
We found that OSA symptoms, such as snoring and pauses in 
breathing during sleep, did not impact on the severity of psycho-
pathology, including depressive, psychotic, and manic symptoms, 
except anxiety symptoms. Disrupted sleep was associated with 
more severe symptoms in all domains measured. We are not 
aware of any previous studies examining the associations between 
OSA and psychopathology in people with psychosis; however, 
a number of case studies have reported a reduction in positive 
and negative symptoms of psychosis when Continuous Positive 
Airway Pressure (CPAP) treatment was initiated (38–41).
Our results revealed an unexpected finding. People prescribed 
with more obesogenic and sedative atypical antipsychotics were 
less likely to report subjective sleep disturbances, than those who 
were prescribed other psychotropic drugs. This contradicts an 
TaBle 4 | Univariate associations between participant cardiovascular risks and symptoms of sleep disturbance.
snore Pause Disruptive sleep
N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci)
Triglycerides 
level -criteria from 
iDF criteria
At risk 287 48.2 12.4*** 1.5 (1.2, 1.88) 141 24.2 33.4*** 2.44 (1.79, 3.33) 350 57.3 6.5 1.33 (1.07, 1.66)
Not at risk 247 38.2 73 11.6 333 50.2
Fasting plasma 
glucose level – criteria 
from iDF criteria
At risk 177 49.6 8.9** 1.45 (1.14, 1.86) 76 22 6 1.47 (1.08, 2.02) 205 56 1.2 1.15 (0.9, 1.47)
Not at risk 357 40.3 139 16 478 52.6
Blood pressure systolic 
and diastolic – iDF 
criteria
At risk 406 48.8 30.9*** 1.73 (1.43, 2.1) 168 20.7 11*** 1.54 (1.19, 1.98) 465 54.5 0.6 1.08 (0.89, 1.3)
Not at risk 310 35.5 125 14.6 474 52.7
BMi: overweight – iDF 
criteria
Yes 599 46.5 41.2*** 2.16 (1.7, 2.7) 263 20.8 37.5*** 3.17 (2.16, 4.66) 701 52.8 0.8 0.91 (0.73, 1.13)
No 122 28.7 32 7.7 240 55.3
hDl level – iDF criteria
At risk 286 46.4 5.8 1.32 (1.05, 1.66) 130 21.6 13.1*** 1.74 (1.29, 2.36) 343 54.5 0.4 1.08 (0.86, 1.34)
Not at risk 244 39.5 82 13.6 336 52.7
Metabolic syndrome – 
iDF criteria
At risk 308 50.6 27.4*** 1.84 (1.46, 2.32) 140 23.6 27.2*** 2.26 (1.66, 3.08) 347 55.6 1.7 1.16 (0.93, 1.45)
Not at risk 218 35.7 72 12 327 52
absolute 
cardiovascular 
disease 5-year risk – 
Framingham risk 
equation
High 205 52 13.4*** 1.56 (1.23, 1.98) 92 24 11*** 1.65 (1.23, 2.22) 245 60.3 9.5* 1.45 (1.15, 1.84)
Low 361 41 138 16 461 51.2
any history of 
cardiovascular disease 
(including hypertension 
and stroke)
Yes 263 54.6 43.2*** 2.03 (1.64, 2.52) 124 26.3 35.5*** 2.19 (1.69, 2.84) 300 60.4 12.9*** 1.47 (1.19, 1.82)
No 459 37.1 170 14.0 644 50.9
OR, odds ratio; CI, confidence interval; IDF, International Diabetes Federation; BMI, body mass index; HDL, high density lipoprotein.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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earlier retrospective study, which found that atypical antipsychotic 
medications were independently associated with OSA, and that 
individuals taking atypical antipsychotics had more severe sleep 
apnea when adjusted for BMI, sex, and use of benzodiazepines and 
sleeping aids (42). It has been suggested that the sedative actions 
of atypical antipsychotics may reduce activity of the hypoglossal 
and recurrent laryngeal nerve on upper airway musculature; 
however, this is not reflected in our data. The finding that the 
use of atypical antipsychotics is associated with reduced odds of 
disrupted sleep could be explained by the hypnotic effects of these 
medications, which could possibly cause a reduction in reported 
sleep symptoms. Another explanation for the difference between 
our results and Rishi et al. (42) is that Rishi compared people tak-
ing atypical antipsychotics with participants who were not taking 
any hypnotic medication, whereas we have compared people 
with psychotic illnesses on a variety of typical antipsychotics, 
atypical antipsychotics, mood stabilizers, and benzodiazepines. 
Interestingly, our study showed that the use of mood stabilizers 
and antidepressants was associated with symptoms of OSA. As 
mood stabilizers and antidepressants are commonly used as 
adjunctive medications in psychosis, this finding suggests that the 
prescribing of these drugs may increase the risk of OSA. Another 
possible explanation for this new finding is, people with OSA may 
be more depressed and fatigued and, therefore, more likely to be 
prescribed antidepressants and mood stabilizers.
Pauses in breathing during sleep, indicating the more severe 
form of OSA, were associated with lower rates of employment 
or study. Evaluation of health-related quality of life showed that 
our participants reporting more severe form of symptoms of OSA 
had significant impairments in the domains of independent living 
TaBle 5 | Univariate associations between participant physical activities, quality of life, and symptoms of sleep disturbance.
snore Pause Disruptive sleep
N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci)
Vigorous activity  
(h/week)
0 598 43.2 3.8 1.27 (1.0, 1.6) 254 18.7 7.5** 1.6 (1.14, 2.26) 770 53.7 0.0 1.0 (0.8, 1.27)
>0 137 37.5 45 12.6 198 53.5
Moderate activity  
(h/week)
0 493 41.2 1.0 0.9 (0.74, 1.11) 207 17.6 0.9 1.03 (0.79, 1.36) 664 53.3 0.2 0.96 (0.78, 1.17)
>0 239 43.7 91 17.1 301 54.4
Walk (h/week)
≤2 389 43.4 2.0 1.15 (0.95, 1.39) 169 19.3 4.2 1.3 (1.0, 1.68) 510 54.6 0.8 1.1 (0.9, 1.31)
>2 336 40.1 128 15.5 449 52.5
Total activity  
(h/week)
0 105 47.7 3.4 1.3 (0.98, 1.73) 50 23.4 6.0* 1.53 (1.09, 2.16) 122 54.2 0.0 1.03 (0.77, 1.36)
>0 630 41.2 249 16.6 846 53.6
Mean sD Mean sD
AQoL (log) No 985 −0.39 0.38 NS 1377 −0.37 0.35 P < 0.001
 Yes 713 −0.40 0.36 NS 285 −0.47 0.41
Indep living (log) No 1008 −0.07 0.14 NS 1407 −0.07 0.14 P < 0.05
Yes 728 −0.08 0.14 293 −0.09 0.15
Social rel (log) No 991 −0.26 0.32 NS 1389 −0.25 0.31 NS
Yes 718 −0.24 0.29 287 −0.26 0.30
Physic sense (log) No 1012 −0.03 0.06 NS 1412 −0.03 0.05 NS
Yes 732 −0.03 0.05 296 −0.03 0.06
Psy well-being (log) No 1009 −0.09 0.15 NS 1409 −0.09 0.14 P = 0.000
Yes 730 −0.10 0.14 294 −0.13 0.18
OR, odds ratio; CI, confidence interval; AQoL (log), algorithms for the Assessment of Quality of Life-4D multi-attribute utility score; Indep living (log), algorithms for independent living; 
Social rel (log), algorithms for social relationships; Physic sense (log), algorithms for physical senses; Psy well-being (log), algorithms for psychological well-being.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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and psychological well-being. It is possible that current sleep 
symptoms may negatively impact on social participation; alter-
natively, people who are disengaged from social activity may also 
sleep poorly, perhaps as a result of depression or poor physical 
health. However, if sleep disorders do cause a reduction in social 
function, treatment of these disorders could be associated with 
improved function and productivity. This hypothesis could be 
tested in clinical trials.
In this study, we found that symptoms of sleep apnea and 
symptoms of disrupted sleep impact on different clinical domains 
in people with psychosis. Symptoms of sleep apnea are more likely 
to have negative relationship with people’s cardiometabolic risk, 
social participation, and physical activity, while disrupted sleep 
has stronger association with active psychiatric symptoms. This 
suggests that the mechanism of the effect of sleep apnea on patients’ 
clinical outcomes is different from sleep deprivation alone.
In conclusion, this study provides robust evidence that sleep 
disorders are prevalent in people with psychotic illness and may 
contribute a further risk factor for cardiovascular disease. The 
disease-specific determinants of OSA in people with psychosis 
should be elucidated in future studies. Further investigation and 
treatment of OSA in people with psychosis may be beneficial in 
reducing the burden of cardiovascular disease, productivity, and 
quality of life.
limitations
This study had several limitations: The inherent biases of 
observational data without clear objectives apply to this study. 
The measures of symptoms of sleep apnea are indirect and 
self-reported. This study did not specifically examine the poly-
pharmacy interaction or the medication compliance. Due to the 
nature of cross-sectional study, we can only identify associations 
in the data.
eThics sTaTeMenT
This study was approved by the appropriate institutional human 
research ethics committees at each of the study sites, and have 
therefore been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its 
later amendments. All participants provided written, informed 
consent prior to participation.
aUThOr cOnTriBUTiOns
DL wrote the first draft of the paper, undertook the initial data 
analyses, and collated and edited successive versions of the paper. 
HM has expertise in sleep disorders in people with psychosis 
TaBle 6 | Univariate associations between subjects’ psychopathology at present state and symptoms of sleep disturbance.
snore Pause Disruptive sleep
N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci)
hallucinations, 
delusions, or subjective 
thought disorder in the 
past 1 month
Yes 404 41.5 0.1 1.02 (0.85, 1.24) 182 19.1 4.4 1.28 (0.99, 1.64) 576 57.4 12.9*** 1.41 (1.17, 1.7)
No 331 42.4 117 15.3 393 48.9
any depressive 
symptoms in the past 
1 month
Yes 210 41.5 0.1 0.98 (0.79, 1.2) 97 19.8 2.7 1.25 (0.96, 1.64) 366 70.2 81.1*** 2.67 (2.15, 3.32)
No 525 42.1 202 16.5 603 46.9
screen for mania over 
the past 1 month
Yes 75 48.4 2.9 1.33 (0.96, 1.85) 23 15.4 0.4 0.85 (0.54, 1.36) 114 72.2 23.8*** 2.4 (1.68, 3.45)
No 660 41.3 276 17.6 855 51.9
Positive general rating 
of anxiety or phobia in 
the past 12 months
Yes 466 44.6 7.8** 1.32 (1.09, 1.6) 209 20.4 15.7*** 1.71 (1.31, 2.24) 663 61.3 63.8*** 2.17 (1.79, 2.63)
No 269 37.9 90 13.0 306 42.2
OR, odds ratio; CI, confidence interval.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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and contributed to interpretation of the data and writing of 
the manuscript. DF has high level statistical skills and has 
undertaken extensive analyses of the SHIP data and written a 
number of papers on the physical health data from SHIP. She 
contributed to the analysis and interpretation of the data and to 
the writing of the manuscript. GW is an endocrinologist who 
has been involved with the SHIP project for many years. He 
contributed to the understanding and interpretation of the data 
and to the final manuscript. VM, DC, AW, AM, and CG were 
part of the team that designed the SHIP project and organized 
the collection of the SHIP dataset. Besides being responsible 
for the original data, they also contributed to the writing of 
the paper and understanding of the SHIP data. AM also made 
additional contributions to the statistical aspects of the paper.
TaBle 7 | Univariate associations between participants’ psychotropic medications and symptoms of sleep disturbance.
snore Pause Disruptive sleep
N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci)
Typical antipsychotics
Yes 156 44.4 1.1 1.14 (0.9, 1.44) 63 18.4 0.3 1.1 (0.8, 1.48) 186 51.7 0.7 0.91 (0.72, 1.14)
No 579 41.3 236 17.2 783 54.1
atypical antipsychotics
Yes 526 41.9 0.0 1.0 (0.81, 1.23) 203 16.5 2.3 0.81 (0.62, 1.06) 651 50.5 18.5*** 0.63 (0.52, 0.78)
No 209 42.0 96 19.6 318 61.6
Mood stabilizer
Yes 237 50.7 20.3*** 1.63 (1.32, 2.02) 92 20 3.9* 1.32 (1.0, 1.73) 251 51.8 1.0 0.9 (0.73, 1.11)
No 498 38.7 207 16.3 718 54.4
antidepressant
Yes 307 47.7 11.1*** 1.39 (1.15, 1.69) 126 19.7 3.7 1.28 (0.99, 1.65) 405 60.1 17.9*** 1.52 (1.25, 1.84)
No 428 38.9 173 16.1 564 49.8
clozapine
Yes 118 41.7 0.0 1.0 (0.76, 1.28) 49 17.6 0.0 1.0 (0.72, 1.42) 126 42.6 17.5*** 0.59 (0.46, 0.75)
No 617 42.0 250 17.4 843 55.8
OR, odds ratio; CI, confidence interval.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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TaBle 8 | Univariate associations between substance use and symptoms of sleep disturbance.
snore Pause Disruptive sleep
N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci) N % χ2 (p) Or (95% ci)
alcohol risk (aUDiT)
Low 496 41.7 0.1 1.03 (0.84, 1.26) 185 15.9 5.5* 1.36 (1.05, 1.76) 627 51.1 9.7** 1.37 (1.12, 1.68)
High 239 42.5 114 20.5 342 59
current smoker
No 242 42.2 0.0 0.99 (0.81, 1.21) 75 13.2 10.8*** 1.6 (1.21, 2.13) 297 49.6 5.6* 1.27 (1.04, 1.54)
Yes 490 42.0 223 19.6 663 55.5
cannabis use – past year
<monthly 304 40.6 0.0 1.02 (0.8, 1.3) 136 18.7 0.0 1.0 (0.75, 1.38) 391 51.0 9.8** 1.46 (1.15, 1.86)
≥monthly 176 41.1 79 18.9 264 60.4
amphetamine use – past 
year
<monthly 256 41.6 0.6 0.84 (0.54, 1.31) 130 21.7 6.3* 0.43 (0.22, 0.84) 347 54.8 2.5 1.42 (0.92, 2.2)
≥monthly 36 37.5 10 10.5 62 63.3
Tranquilizers use – past 
year
<monthly 77 45.6 2.2 0.6 (0.3, 1.19) 43 26.1 0.0 0.95 (0.44, 2.03) 108 62.1 5.8* 2.58 (1.17, 5.68)
≥monthly 15 33.3 11 25.0 38 80.9
caffeine (mg/day) 
<200 mg 252 37.3 9.8** 1.37 (1.15, 1.67) 95 14.3 7.4** 1.44 (1.11, 1.88) 372 53.6 0.0 1.0 (0.83, 1.21)
≥200 mg 483 44.8 204 19.4 597 53.7
OR, odds ratio; CI, confidence interval; AUDIT, Alcohol Use Disorders Identification Test.
*p < 0.05.
**p < 0.01.
***p < 0.001.
TaBle 9 | logistic regression model for the relationship between subjects’ Osa symptoms and disease factors.
snore Pause
Unadjusted 
Or (95% ci)
P adjusted Or 
(95% ci)
P Unadjusted Or 
(95% ci)
P adjusted Or 
(95% ci)
P
Physical health
Metabolic syndrome IDF criteria 1.84 (1.46, 2.32) <0.001 0.67 (0.41, 1.05) NS 2.26 (1.66, 3.08) <0.001 0.632 (0.37, 1.09) NS
Absolute cardiovascular disease  
5-year risk equation
1.56 (1.23, 1.98) <0.001 1.16 (0.67, 2.01) NS 1.65 (1.23, 2.22) <0.001 1.325 (0.69, 2.54) NS
Any history of cardiovascular disease 2.03 (1.64, 2.52) <0.001 1.40 (0.85, 2.30) NS 2.19 (1.69, 2.84) <0.001 1.959 (1.19, 3.48) P < 0.05
Physical activities
Vigorous activity (h/week) 1.27 (1.0, 1.6) NS 1.22 (0.72, 2.06) NS 1.6 (1.14, 2.26) <0.01 0.935 (0.48, 1.83) NS
Walk (h/week) 1.15 (0.95, 1.39) NS 1.01 (0.58, 1.75) NS 1.3 (1.0, 1.68) <0.5 0.771 (0.39, 1.52) NS
Total activity (h/week) 1.3 (0.98, 1.73) NS 0.81 (0.43, 1.50) NS 1.53 (1.09, 2.16) <0.5 0.834 (0.39, 1.77) NS
social function
Formal activity (paid or unpaid work,  
or study)
0.97 (0.8, 1.17) NS 1.38 (0.77, 2.50) NS 0.72 (0.56, 0.93) <0.05 1.161 (0.59, 2.30) NS
Paid employment – past year 0.88 (0.72, 108) NS 0.97 (0.47, 2.00) NS 0.62 (0.47, 0.83) <0.01 0.927 (0.39, 2.19) NS
Paid employment – past week 0.95 (0.75, 1.2) NS 0.86 (0.43, 1.71) NS 0.55 (0.39, 0.77) <0.001 0.399 (0.16, 1.01) NS
substance abuse
Alcohol risk (AUDIT) 1.03 (0.84, 1.26) NS 1.59 (1.07, 2.38) P < 0.05 1.36 (1.05, 1.76) <0.05 1.882 (1.15, 3.09) P < 0.05
Current smoker 0.99 (0.81, 1.21) NS 0.77 (0.43, 1.37) NS 1.6 (1.21, 2.13) <0.001 0.746 (0.37, 1.51) NS
Amphetamine use – past year 0.84 (0.54, 1.31) NS 1.53 (0.81, 2.89) NS 0.43 (0.22, 0.84) <0.05 0.562 (0.22, 1.42) NS
Caffeine (mg/day) 1.37 (1.15, 1.67) <0.01 1.60 (1.03, 2.51) P < 0.01 1.44 (1.11, 1.88) <0.001 1.643 (0.94, 2.89) NS
gender 1.43 (1.18, 1.73) <0.001 1.17 (0.76, 1.80) NS 1.01 (0.78, 1.30) NS 1.507 (0.89, 2.54) NS
age 1.77 (1.46, 2.16) <0.001 2.21 (1.45, 3.39) P < 0.001 1.37 (1.06, 1.77) <0.05 1.141 (0.68, 1.91) P < 0.05
BMi 2.16 (1.7, 2.7) <0.001 1.21 (0.73, 2.00) NS 3.17 (2.16, 4.66) <0.001 2.236 (1.09, 4.58) P < 0.05
OSA, obstructive sleep apnea; OR, odds ratio; CI, confidence interval; BMI, body mass index.
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